Maria Hjorth is proposed to join the board of Monsenso as chairman

Maria Hjorth is proposed to join the board of Monsenso as chairman

Monsenso today announces that the board of Directors proposes Maria Hjorth to be elected for the board at the General Assembly on April 14th, 2021.

Monsenso – a leading provider of digital health solutions for mental health – plans to further strengthen the board by nominating a new professional board member with strong qualifications and competencies to support the company’s growth journey: Maria Hjorth, CEO at VP Securities A/S

Maria Hjorth will replace Jukka Pertola, who – as previously announced – will withdraw from the board of directors in order to comply with good board governance practices by reducing his number of board positions.

The board and the management of Monsenso would like to thank Jukka Pertola for his efforts in supporting the management, the company in general and particularly the listing on Nasdaq First North in 2020.

The new board plans to constitute itself with Maria Hjorth as the Chairman and Jakob Bardram as the Vice Chairman following the ordinary Annual General Meeting on April 14, 2021, where Jukka Pertola is expected to resign as the Chairman.

The nomination of Maria Hjorth follows a change in the board in January, where Peter Høngaard Andensen and Jacob Hahn Michelsen were elected with the aim to strengthen the competences and diversity of the board.

Jukka Pertola commented: ”It is sad to pass on the chairmanship, but I have to do so to comply with demands related to good corporate governance. On the other hand, I am very pleased that with Maria Hjorth and the changes made in January, we have a competent and experienced board that is well positioned to help Monsenso reach the next level. Jacob Hahn Michelsen and Peter Høngaard Andersen brought extensive experience in pharma- and health-related software, medical applications, science and research, pharmaceuticals, neurology, innovation and funding. Maria Hjorth’s experiences from top management, financial businesses, investor relations and M&A is a great supplement to the rest of the board”.

To read the Danish version, click here.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

The EcoWeb project has recruited more than 1600 participants across four countries despite COVID-19

The EcoWeb project has recruited more than 1600 participants across four countries despite COVID-19

Since the EcoWeB project launched MyMoodCoach (an app powered by Monsenso) in November 2020 it has recruited more than 1600 young participants in Belgium, UK, Spain and Germany.

The EcoWeB research study, led by Professor Ed Watkins University of Exeter, seeks to understand what influences mood, how emotions change over time, and which emotional skills increase well-being among youth.

The participants are asked to use MyMoodCoach to monitor their emotions in daily life, while giving them access to “Tools” and “Challenges” to boost their mental health and wellbeing. ‘Tools’ provide the participants with strategies to help them if they feel sad, stressed, anxious or have a problem. ‘Challenges’ help them to learn new skills, develop a positive mindset, improve their confidence and gain insight into their emotions.

The strong pick up of MyMoodCoach reflects a desire among youth to take better care of their mental wellbeing.

“We are very pleased to contribute to this project, as young people have been particularly impacted by COVID-19.” says Thomas Lethenborg, CEO of Monsenso. “Mobile health solutions have proved true value during the pandemic, allowing both clinical practice and important research projects to continue despite lockdowns.”

About the project:

The EcoWeB project is led by Professor Ed Watkins, University of Exeter, and involves 13 different institutions across 8 European nations (the UK, Germany, Belgium, Spain, Greece, the Czech Republic, Denmark, and Switzerland). The project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 754657.

About Monsenso digital health solution:
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

Monsenso expands in the Middle East with new million deal with global pharmaceutical company

Monsenso expands in the Middle East with new million deal with global pharmaceutical company

Monsenso has entered a new million agreement with a global pharmaceutical company and hereby expands its activities to six countries in the Middle East. As part of the agreement, Monsenso will provide its solution for patient monitoring and treatment support in the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar and Bahrain.

Monsenso’s solution will be used to support the treatment of depression and schizophrenia. Patients are provided with an app, which is used to collect real-time patient-reported information and to give patients access to information about their disorder between consultations. Therapists gain access to a clinical web portal and can follow their patients remotely and gain valuable information about behavior, medication intake and symptoms and thus be able to provide a data-driven treatment and allow for proactive follow-up.
In addition, the solution supports communication between patients and therapists.

“We are very pleased with this agreement, which contributes to both expanding our geographic market coverage and our business with pharmaceutical companies in line with our growth strategy. ” says Thomas Lethenborg, CEO of Monsenso. “Depression and schizophrenia are among the most costly disorders for society and have major consequences for affected patients and relatives. Therefore, we are proud to be able to contribute to better treatment within these disease areas.”

The project will not affect Monsenso’s previously communicated plans and guidance for the 2020 financial year.

To read the Danish version, click here.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Monsenso is expanding in the UK with a new Sales Office and hiring of Area Sales Manager

Monsenso is expanding in the UK with a new Sales Office and hiring of Area Sales Manager

Monsenso A/S is establishing an office in the UK to support the growth plan and is hiring Michelle Woolley as Area Sales Manager.

Monsenso, a technology leader in mobile health (mHealth) solutions for mental health is opening an office in London; Monsenso UK Ltd. to strengthen and support the expansion of the business in the UK, the company has hired Michelle Woolley as Area Sales Manager.

Michelle comes to Monsenso with a strong experience in sales management and business development from both Medtech and the pharmaceutical industry from i.e. Pfizer, 3M Healthcare, Servier, and Icentia

Michelle has a Microbiology degree BSc (Hons) from University of Bristol.

Michelle Woolley starts November 9, 2020.

With the opening of an office in the UK and the hiring of Michelle, we continue Monsenso’s international expansion in line with our growth strategy. Michelle will be an important addition to the team and we look forward to welcoming her”, says CEO Thomas Lethenborg.

Click on the link to read the press release in Danish.

For additional information, please contact:

Bettina van Wylich-Muxoll
Marketing
Monsenso
+45 22 70 47 24
marketing@monsenso.com

A smartphone app that can help psychiatrists diagnose mental illness

A smartphone app that can help psychiatrists diagnose mental illness

“A smartphone app that can help psychiatrists diagnose mental illness” –  Peter Hagelund, a Monsenso user, speaks about his experience using the Monsenso mobile health solution to support his treatment, and how it has helped  him improve the communication with his psychiatrist.

Prior to using the Monsenso smartphone app, Peter and his psychiatrist followed the typical therapeutic setting, they would schedule an appointment every two-three weeks, and they would have a conversation to discuss Peter’s previous weeks.  Peter would usually say that he had been doing fine for each appointment, but sometimes he forgot important details that he wanted to discuss.

“It can be pretty tricky to remember, two weeks later [between appointments] how you actually felt that day. With the app it’s really easy to go back and see if your mood has been pretty stable over the last two months, or if you had had some ups and downs over a period,” says Peter Hagelund.

Now, instead of relying on Peter’s memory during the appointment, his psychiatrist can access his data and see how he has been doing, as it happened. He can view how much he has been sleeping, how much he exercises, how much he drinks, how much anxiety he has, and other relevant aspects to his treatment and his disorder.

“My psychiatrist now says things like You say you’ve been doing fine, but I can actually see that you’ve had a few ups and downs. I think the app helps him get a real view of how I have been doing,” says Peter Hagelund.

In his Danish documentary series “Jeg savner min sygdom” (which translates to “I miss my illness”), Peter Hagelund talks about his experience of getting the wrong diagnosis and how finally after six years he got the right diagnosis and treatment. 

In 2014, he was diagnosed with Bipolar Disorder Type 2.

During his whole life, he knew there was something different about him. He always struggled with depression and anxiety, and what eventually turned out to be hypomania. When he was 22, he had his first big episode of depression and began taking antidepressants. However, it took six more years before he was officially diagnosed with Bipolar Disorder Type 2.

He says that one of the trickiest things about having this diagnosis is that he does not experience the typical manic episode where a person feels over-energetic and nearly psychotic. Instead, he feels hypomanic, which means that he is socially well functioning. He is not psychotic. He just feels really well; the problem with this, was that he didn’t feel the need to inform his psychiatrist the fact that he was feeling too well

His psychiatrist found out that he had Bipolar Disorder was because he couldn’t come out of his depression. At first, he was diagnosed with depression and ADD. But these diagnoses didn’t seem to fit because he still had strong mood swings and a lot of anxiety. When he was diagnosed with Bipolar Disorder Type 2, it actually made sense to him. Suddenly, he could see why he had felt the way he had most of his life.

“I really believe that the Monsenso smartphone app could have helped my psychiatrist give me the right diagnosis at an earlier stage because the app helps me to keep track of my mood and to become more aware of how I feel. With the app, I have to pause and take a moment to think about how I’ve actually been doing before entering my answers. Keeping track of all this information has helped my treatment. My psychiatrist and I can plan better on how to avoid my future depressive or hypomanic episodes because we can clearly identify when I am having mood swings”. says Peter Hagelund.  

In August 2018, his documentary about living with Bipolar Disorder aired on national Danish television and the response was overwhelming. Many people contacted him, to thank him for talking about his illness. He made the documentary so other people who have this illness, do not feel ashamed of it.

“My hope is that in the future people are diagnosed at an earlier stage than I was and I truly believe the Monsenso app is one of the things that can help. I really hope that other psychiatrists and their patients will start using the app,” he added.

Click here to read this story in Danish.